Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Consensus Rating of "Buy" from Brokerages

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) have been given an average rating of "Buy" by the six brokerages that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $25.17.

A number of equities analysts recently issued reports on CNTA shares. BMO Capital Markets increased their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a research report on Monday, September 16th. Jefferies Financial Group boosted their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. Oppenheimer reaffirmed an "outperform" rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Morgan Stanley raised Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. Finally, B. Riley began coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a "buy" rating and a $33.00 target price for the company.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock traded up $0.36 during midday trading on Friday, reaching $16.50. 598,945 shares of the stock traded hands, compared to its average volume of 392,096. Centessa Pharmaceuticals has a fifty-two week low of $5.58 and a fifty-two week high of $17.59. The company has a current ratio of 13.29, a quick ratio of 13.29 and a debt-to-equity ratio of 0.27. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -10.35 and a beta of 1.47. The firm has a fifty day moving average price of $15.55 and a two-hundred day moving average price of $11.80.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). On average, equities research analysts forecast that Centessa Pharmaceuticals will post -1.68 earnings per share for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 4,169 shares of the firm's stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the completion of the transaction, the chief executive officer now directly owns 827,755 shares in the company, valued at $10,197,941.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Saurabh Saha sold 4,169 shares of the firm's stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total value of $51,362.08. Following the completion of the sale, the chief executive officer now owns 827,755 shares of the company's stock, valued at $10,197,941.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Gregory M. Weinhoff sold 25,000 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.00, for a total value of $375,000.00. Following the transaction, the insider now directly owns 223,369 shares in the company, valued at $3,350,535. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 325,031 shares of company stock valued at $5,213,043 over the last three months. Company insiders own 11.59% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP boosted its position in Centessa Pharmaceuticals by 66.1% during the third quarter. GSA Capital Partners LLP now owns 93,658 shares of the company's stock valued at $1,498,000 after purchasing an additional 37,275 shares during the last quarter. Atria Investments Inc lifted its holdings in shares of Centessa Pharmaceuticals by 7.0% during the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company's stock valued at $274,000 after buying an additional 1,116 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Centessa Pharmaceuticals by 99.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company's stock worth $217,000 after buying an additional 6,785 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock valued at $40,000 after acquiring an additional 826 shares in the last quarter. Finally, Harbour Capital Advisors LLC acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at approximately $259,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.